BioWorld Asia

July 11, 2007

Silence Signs AstraZeneca To $400M Respiratory Drug Deal

In its largest deal to date, RNAi firm Silence Therapeutics plc is partnering with AstraZeneca plc in a potential £200 million (US$400 million) to develop drugs against respiratory disease targets. (BioWorld International) Read More

CureVac Receives €13M To Boost mRNA Cancer Vaccines

No Abstract Read More

One Bad SNP Carries Variant Linked To Bowel Cancer Risk

Neuropharm Gets Patients' Group Support For Autism Program

Other News To Note

GW Expands Cannabis Franchise Into CNS, Oncology Indications

EU Prediction: Europe's Biotech Future Will Depend On Change

To-BBB Raises $5.4 Million For CNS Drug Delivery

Today's news in brief

BioWorld

BioWorld briefs for March 12, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...